Correction to: “Cardiovascular Benefits of Empagliflozin Are Associated With Gut Microbiota and Plasma Metabolites in Type 2 Diabetes”

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681615/
https://www.ncbi.nlm.nih.gov/pubmed/36104307
http://dx.doi.org/10.1210/clinem/dgac506

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681615/
https://www.ncbi.nlm.nih.gov/pubmed/36104307
http://dx.doi.org/10.1210/clinem/dgac506

Ejemplares similares